Department of Biomorphological and Functional Sciences, University Federico II, Naples, Italy.
Ann Nucl Med. 2012 Oct;26(8):670-5. doi: 10.1007/s12149-012-0624-1. Epub 2012 Jul 1.
We compared metaiodobenzylguanidine (MIBG) uptake and magnetic resonance (MR) signal intensity ratio in differentiating benign and malignant disease in patients with pheochromocytoma or paraganglioma.
Eighteen patients (9 men, mean age 37 ± 8 years) with pheochromocytoma or paraganglioma underwent MR imaging and iodine-131 MIBG scintigraphy. MR signal intensity ratio was measured on T1 and T2-weighted images using region of interest analysis and intensity ratio of MIBG uptake was calculated for each tumor lesion on 48 h images.
A total of 28 tumor lesions was analyzed of which 12 were benign and 16 malignant. MIBG uptake intensity ratio was significantly higher in malignant lesions compared to benign (5.2 ± 2.4 and 2.9 ± 1.4, respectively, p < 0.01). On the contrary, no significant difference in tumor size and MR signal intensity ratio between malignant and benign tumor lesions was observed.
In patients with pheochromocytoma or paraganglioma, iodine-131 MIBG uptake is able to differentiate between benign and malignant disease, while MR imaging is not useful for this purpose. The higher MIBG uptake observed in malignant lesions could reflect major tumor storage of catecholamines compared to benign lesions.
我们比较了间碘苄胍（MIBG）摄取和磁共振（MR）信号强度比值在鉴别嗜铬细胞瘤或副神经节瘤患者的良恶性疾病中的作用。
18 例（9 例男性，平均年龄 37 ± 8 岁）嗜铬细胞瘤或副神经节瘤患者接受了 MR 成像和碘-131 MIBG 闪烁显像。采用感兴趣区分析方法测量 T1 和 T2 加权图像上的 MR 信号强度比，并对 48 小时图像上的每个肿瘤病变计算 MIBG 摄取强度比。
共分析了 28 个肿瘤病变，其中 12 个为良性，16 个为恶性。与良性肿瘤相比，恶性肿瘤的 MIBG 摄取强度比显著升高（分别为 5.2 ± 2.4 和 2.9 ± 1.4，p < 0.01）。相反，恶性和良性肿瘤病变之间的肿瘤大小和 MR 信号强度比无显著差异。
在嗜铬细胞瘤或副神经节瘤患者中，碘-131 MIBG 摄取能够区分良恶性疾病，而 MR 成像对此无帮助。恶性病变中观察到的更高的 MIBG 摄取可能反映了与良性病变相比，肿瘤对儿茶酚胺的大量储存。
Zotero 插件